AI-driven drug research and development (R&D) is breaking
new ground, providing faster and more effective treatment options
for more patients worldwide
SHENZHEN & HONG
KONG, China, Nov. 24,
2022 /PRNewswire/ -- XtalPi announced today that they
are embarking on a strategic collaboration with CK Life Sciences, a
member of the CK Hutchison Group. XtalPi and CK Life Sciences will
leverage their respective expertise to jointly develop a novel AI
tumour vaccine R&D platform to improve the discovery and design
capabilities of tumour vaccines and accelerate the development of
more vaccine types. The goal of this collaboration is to realize
precision treatment for patients worldwide.
According to public information, there were nearly 20 million
newly diagnosed cancer patients worldwide in 2021, of which about
4.5 million cases came from China.
Many cancer types lead to detrimental outcomes, with high morbidity
and mortality, and there remains a large unmet clinical need.
Tumour vaccines targeting different tumour neoantigens,
tumour-associated antigens (TAA) and tumour-specific antigens (TSA)
in patients can be designed for use as immunotherapy, to activate
the patient's own specific immune responses.
Currently, there are only two therapeutic tumour vaccines—
sipuleucel-T for melanoma and Bacillus Calmette-Guérin (BCG) for
bladder cancer, as well as preventive tumour vaccines against human
papillomavirus infection and hepatitis B infection approved by the
U.S. Food and Drug Administration (FDA). Recently, several other
tumour vaccines have entered clinical development and evidence of
efficacy has begun to emerge.
According to Mordor Intelligence, the global cancer vaccine
market size was US$6.79 billion in
2021 and will increase at a compound annual growth rate of 11.53%
from 2022 to 2026. The expected market size by 2026 will be
approximately US$12 billion.
Currently, the design and preclinical development process for
tumour vaccines is complex and lengthy, hindering the efficiency
and success rate of tumour vaccine research and development.
Incorporating XtalPi's industry expertise in AI computation and
robotic automation, this collaboration aims to build an AI tumour
vaccine R&D platform that applies advanced AI algorithms and
high-precision molecular modeling to predict and design a variety
of tumour vaccines that can activate specific immune responses to
kill tumours. The tumour vaccines will be screened and verified
through automated experiments, and through integrating algorithmic
feedback to optimise activity and efficacy, the platform is
expected to generate preclinical tumour vaccine candidate compounds
with robust immune activity.
Dr. Shuhao Wen, co-founder and
chairman of XtalPi, comments: "As a company headquartered in the
Hetao Shenzhen-Hong Kong Science and Technology Innovation
Cooperation Zone, XtalPi is committed to realising the synergies
between Shenzhen and Hong Kong by creating a new paradigm for
innovation in the Greater Bay Area. Empowered by the latest
technological advancements in automation, artificial intelligence
is accelerating more innovative and diverse areas in drug research
and development. Together with CK Life Sciences, we are committed
to overcome conventional limitations and discover diverse
applications for cutting-edge technologies. We believe the AI
cancer vaccine platform jointly developed by CK Life Sciences and
XtalPi will inspire the global scientific community to progress
vaccine research and development and fast-track key development
milestones for cancer vaccines. We are confident that this
collaboration will significantly facilitate the scientific research
exchange in the Greater Bay Area."
Dr. Melvin Toh, Vice President
and Chief Scientific Officer of CK Life Sciences, comments: "The
R&D of tumour vaccines is one of the key development directions
of CK Life Sciences. The cooperation with XtalPi will apply
XtalPi's AI algorithm, molecular modeling and automated experiments
to speed up the R&D process, improve the success rate, and
increase the efficacy of tumour vaccines."
Founded in 2014, XtalPi founders recognized a common hurdle in
drug development having to do with solid polymorphism, which could
be successfully tackled with quantum physics predictions. Since
then, XtalPi has maintained its focus on identifying and then
attacking traditional bottlenecks in biopharmaceutical R&D
through innovative technologies. Through considerable capital
investments in automation and personnel, XtalPi now has four
locations worldwide and employs approximately 1000 employees.
XtalPi has engaged in collaboration research with nearly all top-20
pharmaceutical companies in the world. Its ID4 platform combines
physics-based simulations with experimental validation and
refinement, automation for rapid synthesis, and machine learning to
continuously improve prediction accuracy and process
About CK Life Sciences
CK Life Sciences (stock code: 0775) is listed on the Stock
Exchange of Hong Kong. Bearing the
mission of improving the quality of life, CK Life Sciences is
engaged in the business of research and development, manufacturing,
commercialisation, marketing, sale of, and investment in, products
and assets which fall into three core categories - nutraceuticals,
pharmaceuticals and agriculture-related. CK Life Sciences is a
member of the CK Hutchison Group.
View original content to download
SOURCE XtalPi Inc.